Natriuretic Peptide Testing in Heart Failure
2011; Lippincott Williams & Wilkins; Volume: 123; Issue: 18 Linguagem: Inglês
10.1161/circulationaha.110.979500
ISSN1524-4539
Autores Tópico(s)Cardiac Valve Diseases and Treatments
ResumoHomeCirculationVol. 123, No. 18Natriuretic Peptide Testing in Heart Failure Free AccessResearch ArticlePDF/EPUBAboutView PDFView EPUBSections ToolsAdd to favoritesDownload citationsTrack citationsPermissionsDownload Articles + Supplements ShareShare onFacebookTwitterLinked InMendeleyReddit Jump toSupplemental MaterialFree AccessResearch ArticlePDF/EPUBNatriuretic Peptide Testing in Heart Failure Han-Na Kim and James L. JanuzziJr Han-Na KimHan-Na Kim From the Cardiology Division, Massachusetts General Hospital, Boston MA. and James L. JanuzziJrJames L. JanuzziJr From the Cardiology Division, Massachusetts General Hospital, Boston MA. Originally published10 May 2011https://doi.org/10.1161/CIRCULATIONAHA.110.979500Circulation. 2011;123:2015–2019Case presentation 1: A 78-year-old woman with a history of morbid obesity, coronary artery disease, chronic obstructive pulmonary disease, and chronic kidney disease (serum creatinine 2.0 mg/dL) presented to the emergency department with worsening dyspnea. Her ECG shows no acute ischemic changes; her chest radiograph reveals chronic emphysematous changes with mild bilateral infiltrates. Her lung examination is notable for diffuse wheezing, and she has chronic lower extremity edema. Her amino-terminal pro-B-type natriuretic peptide ( NT-proBNP) level is 5500 pg/mL (upper limit of normal is 75 years). Does this patient have acutely decompensated heart failure (ADHF)?Overview: Natriuretic Peptides in Acute DyspneaMany patients presenting with acute dyspnea (including those with ADHF) have multiple coexisting medical disorders that may complicate their diagnosis and management. Diagnostic uncertainty in the setting of acute dyspnea is associated with longer hospital length of stay, more diffuse diagnostic and therapeutic efforts, increased healthcare costs, and higher likelihood for repeat heart failure (HF) hospitalization or death.1 The addition of testing for brain natriuretic peptide (BNP) or NT-proBNP to standard clinical assessment has been shown to be valuable for an accurate and efficient diagnosis and prognostication of HF, and the use of BNP or NT-proBNP may be associated with improved clinical outcomes.2–4Pathophysiology of Natriuretic Peptides in Heart FailureCirculating levels of BNP/ NT-proBNP are normally very low in healthy individuals. In response to increased myocardial wall stress due to volume- or pressure-overload states (such as in HF), the BNP gene is activated in cardiomyocytes. This results in the production of an intracellular precursor propeptide (proBNP108); further processing of this propeptide results in release of the biologically inert amino-terminal fragment ( NT-proBNP) and the biologically active BNP (Figure 1). In addition, a significant portion of BNP or NT-proBNP detected by current assays includes uncleaved proBNP108, whereas BNP concentrations also include the detection of various subfragments that arise from the degradation of the intact BNP hormone. The biological activity of BNP includes stimulation of natriuresis and vasorelaxation; inhibition of renin, aldosterone, and sympathetic nervous activity; inhibition of fibrosis; and improvement in myocardial relaxation.Download figureDownload PowerPointFigure 1. Biology of the natriuretic peptide system. BNP indicates brain natriuretic peptide; NT-proBNP, amino-terminal pro-B-type natriuretic peptide; and DPP-IV, dipeptidyl peptidase-4.Although released in a 1:1 ratio, the measured NT-proBNP level is higher than that of BNP, in part because NT-proBNP is passively cleared from the circulation more slowly (half-life of 120 versus 20 minutes). Unlike BNP, NT-proBNP is not cleared by natriuretic peptide (NP) receptors or neutral endopeptidases. Rather, NT-proBNP is cleared by various organs, including the skeletal tissue, liver, and kidneys.5 A common misconception is that NT-proBNP is more dependent on renal function for clearance than is BNP; both are equally cleared by the kidneys.6Diagnostic Applications of Brain Natriuretic Peptide or Amino-Terminal Pro-B-Type Natriuretic Peptide in Acutely Decompensated Heart FailureBrain natriuretic peptide and NT-proBNP levels are increased in HF, and correlate well with ventricular wall stress and severity of HF.2,7 The Breathing Not Properly Multinational Study2 and the Pro-BNP Investigation of Dyspnea in the Emergency Department7 showed that NP levels were more accurate for diagnosis or exclusion of ADHF than clinical judgment, particularly in the context of diagnostic uncertainty.8 When added to comprehensive clinical assessment, BNP and NT-proBNP are both incrementally useful for diagnosis of ADHF, and both are endorsed in current practice guidelines for HF evaluation (particularly when diagnostic indecision is present).9Interpretation and Differential Diagnosis of Elevated Natriuretic Peptide LevelsElevated concentrations of BNP or NT-proBNP are powerfully associated with the presence of HF; however, there is no value for either that is 100% diagnostic for HF. Both BNP and NT-proBNP may be elevated in a number of other disease states, and patient factors may influence results.Among HF syndromes, systolic dysfunction and HF with preserved ejection fraction may cause elevated BNP or NT-proBNP, although HF with preserved ejection fraction may be associated with lower values of both peptides than HF due to systolic dysfunction.10 In addition, other relevant cardiac diagnoses, including right ventricular failure (due to primary cardiac pathology or secondary to pulmonary embolism or pulmonary hypertension),11 valvular heart disease,12 and arrhythmias such as atrial fibrillation13 may cause elevation of BNP or NT-proBNP. In addition to cardiovascular variables that influence NP concentrations, advancing age and renal dysfunction may lead to higher values without overt HF, whereas obesity may result in unexpectedly lower BNP or NT-proBNP concentrations, even in those with HF.14,15Overall, the recommended approaches for use of BNP or NT-proBNP for the exclusion and identification of ADHF work well. To troubleshoot complex situations such as renal disease,16,17 adjustment in cutoff points may help (Table).Table. Suggested Cut Points for BNP and NT-proBNP Use in Several SituationsCutoff Value, pg/mLSensitivity, %Specificity, %PPV, %NPV, %ReferenceTo exclude ADHF BNP<30–50976271962 NT-proBNP<300996862997To identify ADHF Single cutoff point strategy BNP<100907679892 NT-proBNP<900908576947 Multiple cutpoint strategy BNP, gray zone approach 400 to rule in63918674 NT-proBNP, age-stratified approach<450 for age <50 y9084886619<900 for age 50–75 y 75 ySpecial situations Renal dysfunction (GFR <60 mL · min · 1.73 m−2) BNP<2008863837217 NT-proBNP(1) <1200, all ages8972749416or(2) age-stratified approach, above Obesity BNP170 for BMI <25 kg/m29077789015110 for BMI 25–35 kg/m29077779054 for BMI ≥35 kg/m291707091 NT-proBNP<900, no adjustment for BMI8776799014Age-stratified cut points, no adjustment for BMI86908595PPV indicates positive predictive value; NPV, negative predictive value; ADHF, acutely decompensated heart failure; BNP, brain natriuretic peptide; NT-proBNP, amino-terminal pro-B-type natriuretic peptide; GFR, glomerular filtration rate; and BMI, body mass index.*indicates not applicable.Another important situation is the patient with a gray zone BNP or NT-proBNP value. Approximately 20% of patients with acute dyspnea have BNP or NT-proBNP levels that are above the cutoff point to exclude HF but too low to definitively identify it. Knowledge of the differential diagnosis of non-HF elevation of NP, as well as interpretation of the BNP or NT-proBNP value in the context of a clinical assessment, is essential20; gray zone values are not without prognostic meaning, however, and should be approached with caution.20In our patient, if the initial BNP concentration had been 90 pg/mL (upper limit of normal is <200 pg/mL for renal dysfunction), or if her NT-proBNP had been 450 pg/mL, in an elderly female with renal dysfunction, ADHF would be less likely as the primary cause of her symptoms. However, we should keep in mind that HF with preserved ejection fraction might be present, or values might have been low because of her morbid obesity. On the other hand, her NT-proBNP of 5500 pg/mL is most consistent with ADHF, irrespective of age or renal function. As before, interpretation of the NP result in the clinical context is very important.Natriuretic Peptides and Prognosis in Heart FailureAcross all stages of HF, elevated BNP or NT-proBNP concentrations are at least comparable prognostic predictors of mortality and cardiovascular events relative to traditional predictors of outcome in this setting,21 with increasing NP concentrations predicting worse prognosis in a linear fashion. This prognostic value may be used to stratify patients at the highest risk of adverse outcomes (Figure 2).22Download figureDownload PowerPointFigure 2. Age-adjusted Kaplan-Meier survival curve of mortality at 1 year associated with an elevated amino-terminal pro-B-type natriuretic peptide ( NT-proBNP) concentration at emergency department presentation with dyspnea in those with acutely decompensated heart failure. Reproduced from Januzzi et al22 with permission of the publisher. Copyright © 2006, American Medical Association.In ADHF, an initial value of BNP or NT-proBNP is prognostically useful; however, a follow-up measurement after therapy provides incremental prognostic value. Observational studies suggest that when BNP/ NT-proBNP concentrations decrease by 30% or more in this setting, a better prognosis is expected than when values fail to decrease or actually increase.23 However, prospective randomized studies definitively supporting in-hospital monitoring are not yet available.Future Directions: Natriuretic Peptides for Guided Management of Chronic Heart FailureCase Presentation 2: The 78-year-old woman discussed in case 1 is found to have an ejection fraction of 35% and is treated with a loop diuretic, as well as with maximum-dose angiotensin-converting enzyme inhibition and carvedilol. She is discharged home and seen in her cardiologist's office for follow-up, where she feels physically as she did at her baseline examination, with only mild dyspnea on maximal exertion. Her NT-proBNP level is 2150 pg/mL; on recheck 3 months later, it is 4800 pg/mL, but she remains unchanged clinically. What is the meaning of this finding, and how might the clinician respond?Elevated BNP (above approximately 125 pg/mL) or NT-proBNP (above approximately 1000 pg/mL) values are prognostically meaningful in chronic HF, and a rising pattern is predictive of impending adverse outcome, irrespective of other subjective and objective prognostic metrics. Furthermore, therapies that are favorable for chronic HF (such as β-blockers, vasodilators, or aldosterone blockers) tend to lower concentrations of BNP or NT-proBNP. Thus, there is increasing interest in guiding HF therapy with BNP or NT-proBNP, with the goal of lowering concentrations of these markers (and maintaining their suppression) as part of the therapeutic approach in HF. Although evidence is increasing that NP-guided outpatient management of HF may improve clinical outcomes,4 more information is needed before adoption of such an approach, which is currently being tested in clinical trials.24 Nonetheless, an HF patient on an ostensibly stable medication program with a rising NP concentration is at high risk for adverse outcome and should be scrutinized closely for opportunities to optimize management.Follow-Up of Cases 1 and 2The optimal treatment strategy for our 78-year-old patient in case 1 would be to ascertain the cause of ADHF, while simultaneously administering decongestive therapy with intravenous loop diuresis. In the meantime, optimization of her HF medical regimen, including uptitration of the angiotensin-converting enzyme inhibitor dose and a review of and potential increase in the dose of her β-blocker (when safely able to do so) would be indicated; the addition of an aldosterone blocker is recommended if persistent New York Heart Association functional class III or IV symptoms are present. Follow-up NP measurement at the time of discharge would be useful to ensure adequacy of therapy, while serving to facilitate a smooth transition to outpatient management.In case 2, an increasing NP concentration in a seemingly unchanged outpatient with chronic HF should prompt assessment and reaction. Among the causes of a rising BNP or NT-proBNP in a seemingly stable outpatient are noncompliance with medication, an inadequate medication program, dietary indiscretions, coronary ischemia, atrial arrhythmia, and progressive decline in cardiovascular function. In this context, whether or not the patient appears to be on a maximal treatment program, reassessment of the patient is indicated. This includes possible investigation for causes of a rising NP value, as well as simultaneous uptitration of medications when possible; consideration for eligibility for therapies such as cardiac resynchronization therapy or implantable-cardioverter defibrillator implantation is also reasonable.AcknowledgmentsThe authors would like to thank Drs Paul Clopton, Lori Daniels, and Alan Maisel for their assistance.DisclosuresDr Januzzi has received significant grant support from Roche Diagnostics, Siemens, and Critical Diagnostics. Dr Kim reports no conflicts.FootnotesCorrespondence to James L. Januzzi, Jr, MD, FACC, Cardiology Division, Massachusetts General Hospital, Yawkey 5984, 55 Fruit St, Boston, MA 02114. E-mail jjanuzzi@partners.orgReferences1. Green SM, Martinez-Rumayor A, Gregory SA, Baggish AL, O'Donoghue ML, Green JA, Lewandrowski KB, Januzzi JL. Clinical uncertainty, diagnostic accuracy, and outcomes in emergency department patients presenting with dyspnea. Arch Intern Med. 2008; 168:741–748.CrossrefMedlineGoogle Scholar2. Maisel AS, Krishnaswamy P, Nowak RM, McCord J, Hollander JE, Duc P, Omland T, Storrow AB, Abraham WT, Wu AH, Clopton P, Steg PG, Westheim A, Knudsen CW, Perez A, Kazanegra R, Herrmann HC, McCullough PA. Rapid measurement of B-type natriuretic peptide in the emergency diagnosis of heart failure. N Engl J Med. 2002; 347:161–167.CrossrefMedlineGoogle Scholar3. Januzzi JL, Peacock WF, Maisel AS, Chae CU, Jesse RL, Baggish AL, O'Donoghue M, Sakhuja R, Chen AA, van Kimmenade RR, Lewandrowski KB, Lloyd-Jones DM, Wu AH. Measurement of the interleukin family member ST2 in patients with acute dyspnea: results from the PRIDE (Pro-Brain Natriuretic Peptide Investigation of Dyspnea in the Emergency Department) study. J Am Coll Cardiol. 2007; 50:607–613.CrossrefMedlineGoogle Scholar4. Felker GM, Hasselblad V, Hernandez AF, O'Connor CM. Biomarker-guided therapy in chronic heart failure: a meta-analysis of randomized controlled trials. Am Heart J. 2009; 158:422–430.CrossrefMedlineGoogle Scholar5. Palmer SC, Yandle TG, Nicholls MG, Frampton CM, Richards AM. Regional clearance of amino-terminal pro-brain natriuretic peptide from human plasma. Eur J Heart Fail. 2009; 11:832–839.CrossrefMedlineGoogle Scholar6. van Kimmenade RR, Januzzi JL, Bakker JA, Houben AJ, Rennenberg R, Kroon AA, Crijns HJ, van Dieijen-Visser MP, de Leeuw PW, Pinto YM. Renal clearance of B-type natriuretic peptide and amino terminal pro-B-type natriuretic peptide: a mechanistic study in hypertensive subjects. J Am Coll Cardiol. 2009; 53:884–890.CrossrefMedlineGoogle Scholar7. Januzzi JL, Camargo CA, Anwaruddin S, Baggish AL, Chen AA, Krauser DG, Tung R, Cameron R, Nagurney JT, Chae CU, Lloyd-Jones DM, Brown DF, Foran-Melanson S, Sluss PM, Lee-Lewandrowski E, Lewandrowski KB. The N-terminal Pro-BNP Investigation of Dyspnea in the Emergency department (PRIDE) study. Am J Cardiol. 2005; 95:948–954.CrossrefMedlineGoogle Scholar8. Steinhart B, Thorpe KE, Bayoumi AM, Moe G, Januzzi JL, Mazer CD. Improving the diagnosis of acute heart failure using a validated prediction model. J Am Coll Cardiol. 2009; 54:1515–1521.CrossrefMedlineGoogle Scholar9. Hunt SA, Abraham WT, Chin MH, Feldman AM, Francis GS, Ganiats TG, Jessup M, Konstam MA, Mancini DM, Michl K, Oates JA, Rahko PS, Silver MA, Stevenson LW, Yancy CW. 2009 Focused update incorporated into the ACC/AHA 2005 guidelines for the diagnosis and management of heart failure in adults: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines: developed in collaboration with the International Society for Heart and Lung Transplantation. Circulation. 2009; 119:e391–e479.LinkGoogle Scholar10. O'Donoghue M, Chen A, Baggish AL, Anwaruddin S, Krauser DG, Tung R, Januzzi JL. The effects of ejection fraction on N-terminal ProBNP and BNP levels in patients with acute CHF: analysis from the ProBNP Investigation of Dyspnea in the Emergency Department (PRIDE) study. J Card Fail. 2005; 11(suppl):S9–S14.CrossrefMedlineGoogle Scholar11. Binder L, Pieske B, Olschewski M, Geibel A, Klostermann B, Reiner C, Konstantinides S. N-terminal pro-brain natriuretic peptide or troponin testing followed by echocardiography for risk stratification of acute pulmonary embolism. Circulation. 2005; 112:1573–1579.LinkGoogle Scholar12. Gerber IL, Stewart RA, Legget ME, West TM, French RL, Sutton TM, Yandle TG, French JK, Richards AM, White HD. Increased plasma natriuretic peptide levels reflect symptom onset in aortic stenosis. Circulation. 2003; 107:1884–1890.LinkGoogle Scholar13. Morello A, Lloyd-Jones DM, Chae CU, van Kimmenade RR, Chen AC, Baggish AL, O'Donoghue M, Lee-Lewandrowski E, Januzzi JL. Association of atrial fibrillation and amino-terminal pro-brain natriuretic peptide concentrations in dyspneic subjects with and without acute heart failure: results from the ProBNP Investigation of Dyspnea in the Emergency Department (PRIDE) study. Am Heart J. 2007; 153:90–97.CrossrefMedlineGoogle Scholar14. Bayes-Genis A, Lloyd-Jones DM, van Kimmenade RR, Lainchbury JG, Richards AM, Ordonez-Llanos J, Santalo M, Pinto YM, Januzzi JL. Effect of body mass index on diagnostic and prognostic usefulness of amino-terminal pro-brain natriuretic peptide in patients with acute dyspnea. Arch Intern Med. 2007; 167:400–407.CrossrefMedlineGoogle Scholar15. Daniels LB, Clopton P, Bhalla V, Krishnaswamy P, Nowak RM, McCord J, Hollander JE, Duc P, Omland T, Storrow AB, Abraham WT, Wu AH, Steg PG, Westheim A, Knudsen CW, Perez A, Kazanegra R, Herrmann HC, McCullough PA, Maisel AS. How obesity affects the cut-points for B-type natriuretic peptide in the diagnosis of acute heart failure: results from the Breathing Not Properly Multinational Study. Am Heart J. 2006; 151:999–1005.CrossrefMedlineGoogle Scholar16. Anwaruddin S, Lloyd-Jones DM, Baggish A, Chen A, Krauser D, Tung R, Chae C, Januzzi JL. Renal function, congestive heart failure, and amino-terminal pro-brain natriuretic peptide measurement: results from the ProBNP Investigation of Dyspnea in the Emergency Department (PRIDE) Study. J Am Coll Cardiol. 2006; 47:91–97.CrossrefMedlineGoogle Scholar17. McCullough PA, Duc P, Omland T, McCord J, Nowak RM, Hollander JE, Herrmann HC, Steg PG, Westheim A, Knudsen CW, Storrow AB, Abraham WT, Lamba S, Wu AH, Perez A, Clopton P, Krishnaswamy P, Kazanegra R, Maisel AS. B-type natriuretic peptide and renal function in the diagnosis of heart failure: an analysis from the Breathing Not Properly Multinational Study. Am J Kidney Dis. 2003; 41:571–579.CrossrefMedlineGoogle Scholar18. McCullough PA, Nowak RM, McCord J, Hollander JE, Herrmann HC, Steg PG, Duc P, Westheim A, Omland T, Knudsen CW, Storrow AB, Abraham WT, Lamba S, Wu AH, Perez A, Clopton P, Krishnaswamy P, Kazanegra R, Maisel AS. B-type natriuretic peptide and clinical judgment in emergency diagnosis of heart failure: analysis from Breathing Not Properly (BNP) Multinational Study. Circulation. 2002; 106:416–422.LinkGoogle Scholar19. Januzzi JL, van Kimmenade R, Lainchbury J, Bayes-Genis A, Ordonez-Llanos J, Santalo-Bel M, Pinto YM, Richards M. NT-proBNP testing for diagnosis and short-term prognosis in acute destabilized heart failure: an international pooled analysis of 1256 patients: the International Collaborative of NT-proBNP Study. Eur Heart J. 2006; 27:330–337.CrossrefMedlineGoogle Scholar20. van Kimmenade RR, Pinto YM, Januzzi JL. Importance and interpretation of intermediate (gray zone) amino-terminal pro-B-type natriuretic peptide concentrations. Am J Cardiol. 2008; 101:39–42.CrossrefMedlineGoogle Scholar21. Sachdeva A, Horwich TB, Fonarow GC. Comparison of usefulness of each of five predictors of mortality and urgent transplantation in patients with advanced heart failure. Am J Cardiol. 106:830–835.CrossrefMedlineGoogle Scholar22. Januzzi JL, Sakhuja R, O'Donoghue M, Baggish AL, Anwaruddin S, Chae CU, Cameron R, Krauser DG, Tung R, Camargo CA, Lloyd-Jones DM. Utility of amino-terminal pro-brain natriuretic peptide testing for prediction of 1-year mortality in patients with dyspnea treated in the emergency department. Arch Intern Med. 2006; 166:315–320.CrossrefMedlineGoogle Scholar23. Bettencourt P, Azevedo A, Pimenta J, Frioes F, Ferreira S, Ferreira A. N-terminal-pro-brain natriuretic peptide predicts outcome after hospital discharge in heart failure patients. Circulation. 2004; 110:2168–2174.LinkGoogle Scholar24. Bhardwaj A, Rehman SU, Mohammed A, Baggish AL, Moore SA, Januzzi JL. Design and methods of the Pro-B Type Natriuretic Peptide Outpatient Tailored Chronic Heart Failure Therapy (PROTECT) Study. Am Heart J. 2010; 159:532–538.e531.CrossrefMedlineGoogle Scholar eLetters(0)eLetters should relate to an article recently published in the journal and are not a forum for providing unpublished data. Comments are reviewed for appropriate use of tone and language. Comments are not peer-reviewed. Acceptable comments are posted to the journal website only. Comments are not published in an issue and are not indexed in PubMed. Comments should be no longer than 500 words and will only be posted online. References are limited to 10. Authors of the article cited in the comment will be invited to reply, as appropriate.Comments and feedback on AHA/ASA Scientific Statements and Guidelines should be directed to the AHA/ASA Manuscript Oversight Committee via its Correspondence page.Sign In to Submit a Response to This Article Previous Back to top Next FiguresReferencesRelatedDetailsCited ByFang M, Wang D, Tang O, McEvoy J, Echouffo‐Tcheugui J, Christenson R and Selvin E (2023) Subclinical Cardiovascular Disease in US Adults With and Without Diabetes, Journal of the American Heart Association, 12:11, Online publication date: 6-Jun-2023. Ben Halima H, Bellagambi F, Hangouët M, Alcacer A, Pfeiffer N, Heuberger A, Zine N, Bausells J, Elaissari A and Errachid A (2023) A novel electrochemical strategy for NT-proBNP detection using IMFET for monitoring heart failure by saliva analysis, Talanta, 10.1016/j.talanta.2022.123759, 251, (123759), Online publication date: 1-Jan-2023. Guo Z, Tian R, Xu W, Yip D, Radyk M, Santos F, Yip A, Chen T and Tang X (2022) Highly accurate heart failure classification using carbon nanotube thin film biosensors and machine learning assisted data analysis, Biosensors and Bioelectronics: X, 10.1016/j.biosx.2022.100187, 12, (100187), Online publication date: 1-Dec-2022. Gronda E, Vanoli E, Iacoviello M, Caldarola P, Gabrielli D and Tavazzi L (2022) The Benefit of Sodium-Glucose Co-Transporter Inhibition in Heart Failure: The Role of the Kidney, International Journal of Molecular Sciences, 10.3390/ijms231911987, 23:19, (11987) Dogheim G, Amralla M and Werida R (2022) Role of neopterin as an inflammatory biomarker in congestive heart failure with insights on effect of drug therapies on its level, Inflammopharmacology, 10.1007/s10787-022-01028-5, 30:5, (1617-1622), Online publication date: 1-Oct-2022. Tucker W, Tucker B, Rye K and Ong K (2022) Fibroblast growth factor 21 in heart failure, Heart Failure Reviews, 10.1007/s10741-022-10268-0, 28:1, (261-272) Chang S, Khakh P, Janzen M, Lee T, Kiess M, Rychel V and Grewal J (2022) Trending Cardiac Biomarkers During Pregnancy in Women With Cardiovascular Disease, Circulation: Heart Failure, 15:8, (e009018), Online publication date: 1-Aug-2022. Dillinger J, Patin C, Bonnin P, Vidal-Trecan T, Paven E, Gautier J, Riveline J, Amah G and Henry P (2021) Elevated Brain Natriuretic Peptide and High Brachial Pulse Pressure in Patients With Diabetes, American Journal of Hypertension, 10.1093/ajh/hpab179, 35:5, (414-422), Online publication date: 10-May-2022. Al-Sadawi M, Saad M, Ayyadurai P, Shah N, Bhandari M and Vittorio T Biomarkers in Acute Heart Failure Syndromes: An Update, Current Cardiology Reviews, 10.2174/1573403X17666210909170415, 18:3 Raj N and Crooks R (2022) Detection Efficiency of Ag Nanoparticle Labels for a Heart Failure Marker Using Linear and Square-Wave Anodic Stripping Voltammetry, Biosensors, 10.3390/bios12040203, 12:4, (203) Herrmann J, Lenihan D, Armenian S, Barac A, Blaes A, Cardinale D, Carver J, Dent S, Ky B, Lyon A, López-Fernández T, Fradley M, Ganatra S, Curigliano G, Mitchell J, Minotti G, Lang N, Liu J, Neilan T, Nohria A, O'Quinn R, Pusic I, Porter C, Reynolds K, Ruddy K, Thavendiranathan P and Valent P (2021) Defining cardiovascular toxicities of cancer therapies: an International Cardio-Oncology Society (IC-OS) consensus statement, European Heart Journal, 10.1093/eurheartj/ehab674, 43:4, (280-299), Online publication date: 31-Jan-2022. Gronda E, Vanoli E, Iacoviello M, Urbinati S, Caldarola P, Colivicchi F and Gabrielli D (2022) Renal effects of SGLT2 inhibitors in cardiovascular patients with and without chronic kidney disease: focus on heart failure and renal outcomes, Heart Failure Reviews, 10.1007/s10741-021-10211-9 Liu L, Ding X, Han Y, Lv J and Khan R (2022) Effects and Safety of Sacubitril/Valsartan for Patients with Myocardial Infarction: A Systematic Review and Meta-Analysis, Journal of Healthcare Engineering, 10.1155/2022/7840852, 2022, (1-8), Online publication date: 5-Jan-2022. LUPU SURLEA A, BASA M, PETCU A, RADU DRĂGOI Ș and ROȘOIU N (2022) Galectins, Aspects in Cardiovascular Diseases, Annals of the Academy of Romanian Scientists Series on Biological Sciences, 10.56082/annalsarscibio.2022.1.45, 11:1, (45-52), . Ampong I (2022) Metabolic and Metabolomics Insights into Dilated Cardiomyopathy, Annals of Nutrition and Metabolism, 10.1159/000524722, 78:3, (147-155), . Huynh J, Masoudi S, Noorbakhsh A, Mahmoodi A, Kligerman S, Yen A, Jacobs K, Hahn L, Hasenstab K, Pazzani M and Hsiao A Deep Learning Radiographic Assessment of Pulmonary Edema: Optimizing Clinical Performance, Training With Serum Biomarkers, IEEE Access, 10.1109/ACCESS.2022.3172706, 10, (48577-48588) Beck F, Horn C and Baeumner A (2022) Dry-reagent microfluidic biosensor for simple detection of NT-proBNP via Ag nanoparticles, Analytica Chimica Acta, 10.1016/j.aca.2021.339375, 1191, (339375), Online publication date: 1-Jan-2022. Beck F, Horn C and Baeumner A (2021) Ag nanoparticles outperform Au nanoparticles for the use as label in electrochemical point-of-care sensors, Analytical and Bioanalytical Chemistry, 10.1007/s00216-021-03288-6, 414:1, (475-483), Online publication date: 1-Jan-2022. Boman K, Lindmark K, Stålhammar J, Olofsson M, Costa-Scharplatz M, Fonseca A, Johansson S, Heller V, Törnblom M and Wikström G (2021) Healthcare resource utilisation and costs associated with a heart failure diagnosis: a retrospective, population-based cohort study in Sweden, BMJ Open, 10.1136/bmjopen-2021-053806, 11:10, (e053806), Online publication date: 1-Oct-2021. Gachpazan M, Mohammadinejad A, Saeidinia A, Rahimi H, Ghayour-Mobarhan M, Vakilian F and Rezayi M (2021) A review of biosensors for the detection of B-type natriuretic peptide as an important cardiovascular biomarker, Analytical and Bioanalytical Chemistry, 10.1007/s00216-021-03490-6, 413:24, (5949-5967), Online publication date: 1-Oct-2021. Jarkovská D, Miklovič M, Švíglerová J, Červenka L, Škaroupková P, Melenovský V and Štengl M (2021) Effects of Trandolapril on Structural, Contractile and Electrophysiological Remodeling in Experimental Volume Overload Heart Failure, Frontiers in Pharmacology, 10.3389/fphar.2021.729568, 12 Huttin O, Fraser A, Lund L, Donal E, Linde C, Kobayashi M, Erdei T, Machu J, Duarte K, Rossignol P, Paulus W, Zannad F and Girerd N (2021) Risk stratification with echocardiographic biomarkers in heart failure with preserved ejection fraction: the media echo score, ESC Heart Failure, 10.1002/ehf2.13251, 8:3, (1827-1839), Online publication date: 1-Jun-2021. Argaiz E (2021) VExUS Nexus: Bedside Assessment of Venous Congestion, Advances in Chronic Kidney Disease, 10.1053/j.ackd.2021.03.004, 28:3, (252-261), Online publication date: 1-May-2021. Wang S, Fontana F, Shahbazi M and Santos H (2021) Acetalated dextran based nano- and microparticles: synthesis, fabrication, and therapeutic applications, Chemical Communications, 10.1039/D1CC00811K, 57:35, (4212-4229) Nicolaou P (2021) Sex differences in heart failure medications targeting the renin-angiotensin-aldosterone system, European Journal of Pharmacology, 10.1016/j.ejphar.2021.173961, 897, (173961), Online publication date: 1-Apr-2021. Bencivenga L, Palaia M, Sepe I, Gambino G, Komici K, Cannavo A, Femminella G and Rengo G (2021) Why Do We Not Assess Sympathetic Nervous System Activity in Heart Failure Management: Might GRK2 Serve as a New Biomarker?, Cells, 10.3390/cells10020457, 10:2, (457) T. Chakrapani A (2021) Biomarkers of Diseases: Their Role in Emergency Medicine Neurodegenerative Diseases - Molecular Mechanisms and Current Therapeutic Approaches, 10.5772/intechopen.94509 Piguillem S, Gamella M, García de Frutos P, Batlle M, Yáñez‐Se
Referência(s)